Eli Lilly plans to submit tirzepatide application at the end of the year
After presenting new results from a comparison study between Eli Lilly's tirzepatide and diabetes drug Lantus, the company is ready to set a time horizon for when it will seek approval for the drug (Updated).
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
A recent study conducted by Eli Lilly shows positive effects of the use of diabetes drug tirzepatide.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly on tirzepatide data: Surpasses our expectations
For subscribers
Eli Lilly surpasses Novo's golden diabetes drug
For subscribers
